Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.
NEJM EvidAug 29, 2026 (epub)
Mats C H Lassen, Sine H Christensen, Marat Yafasov et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the bivalent RSV prefusion F (RSVpreF) vaccine's effectiveness in preventing RSV-related hospitalizations among adults in Denmark and Spain. The study found that the vaccine reduced the incidence of RSV-related respiratory tract disease hospitalization to 0.16 events per 1000 person-years compared to 0.55 in the control group, indicating a vaccine effectiveness of 70.3%.
Key findings
- Vaccine effectiveness for RSV-related RTD hospitalization was 70.3% (95% CI, 49.7-83.2).
- Incidence of RSV-related lower RTD hospitalization was 0.11 vs 0.39 events per 1000 person-years.
- All-cause RTD hospitalization incidence was 11.16 vs 12.01 events per 1000 person-years.
- Serious adverse events occurred in 2.0% of the vaccine group and 2.2% of the control group.
Why it matters
The findings highlight the potential of the RSVpreF vaccine to significantly reduce hospitalizations due to RSV in older adults and those with chronic health conditions, addressing a critical public health concern.